Pharmacyclics Price Target Increased to $180.00 by Analysts at Deutsche Bank (PCYC)
Equities research analysts at Deutsche Bank raised their price target on shares of Pharmacyclics (NASDAQ:PCYC) from $170.00 to $180.00 in a research note issued to investors on Friday, Analyst RN reports. The firm currently has a “buy” rating on the stock. Deutsche Bank’s price target would suggest a potential upside of 26.16% from the company’s current price.
PCYC has been the subject of a number of other recent research reports. Analysts at JMP Securities set a $191.00 price target on shares of Pharmacyclics in a research note on Friday. Separately, analysts at Nomura raised their price target on shares of Pharmacyclics to $166.00 in a research note on Friday. Finally, analysts at Robert W. Baird raised their price target on shares of Pharmacyclics from $163.00 to $173.00 in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Pharmacyclics has an average rating of “Buy” and a consensus price target of $153.06.
Pharmacyclics (NASDAQ:PCYC) traded up 5.10% on Friday, hitting $149.9501. 2,332,963 shares of the company’s stock traded hands. Pharmacyclics has a one year low of $71.85 and a one year high of $145.30. The stock has a 50-day moving average of $131.5 and a 200-day moving average of $122.5. The company has a market cap of $11.053 billion and a P/E ratio of 56.75.
Pharmacyclics (NASDAQ:PCYC) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.95 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.67 by $0.28. The company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $85.69 million. On average, analysts predict that Pharmacyclics will post $0.37 earnings per share for the current fiscal year.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.